Rapid Micro Biosystems (RPID) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached a record $7.6 million, up 24% year-over-year, with the highest system placements since Q3 2021 and a total of 156 systems placed to date.

• Net loss narrowed to $11.3 million ($0.26 per share), improved from $13.4 million ($0.31 per share) in Q3 2023.

• Gross margin turned positive at 8%, a 35 percentage point improvement year-over-year, reflecting cost reduction and efficiency gains.

• Seven Growth Direct systems were placed globally, including a multi-system order from a top 20 pharma customer, highlighting the land-and-expand strategy.

• Operational Efficiency Program launched in July 2024 targets $7 million in annual savings and positive cash flow by end of 2027.

Financial highlights

• Product revenue increased 25% to $5.3 million; service revenue rose 21% to $2.3 million year-over-year.

• Recurring revenue grew 8% to $3.7 million; non-recurring revenue increased 44% to $3.9 million.

• Total cost of revenue decreased 10% to $7.0 million; operating expenses remained flat at $12.7 million.

• Cash, cash equivalents, and investments totaled $61 million as of September 30, 2024, with no debt.

• Nine-month 2024 revenue was $19.8 million, up 22.6% from 2023; net loss for the period was $37.2 million, improved from $41.3 million.

Outlook and guidance

• Full-year 2024 revenue expected to be at least $27 million, implying at least 20% year-over-year growth and at least 20 system placements.

• Q4 consumables revenue expected to be consistent with Q3; service revenue projected between $2.5–$3 million.

• Gross margins expected to increase sequentially in Q4, with service margins higher and product margins stable.

• Operating expenses for 2024 guided to $50–$51 million, with $40 million in expected cash burn.

• Goal to achieve positive cash flow by end of 2027 without additional financing, supported by the Operational Efficiency Program.